C. Cho, A. Jemal, T. Murray, E. Ward, A. Samuels et al., Multidrug resistance (MDR) in cancer mechanisms. Reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs Combined action and regulation of phase II enzymes and multidrug resistance proteins in multidrug resistance in cancer, Mol Cancer Cancer statistics CA Cancer J Clin Eur J Pharm Sci Cancer Treat Rev, vol.645, issue.346, pp.10-1186, 2000.

T. Tsuruo, . Molecular, G. Mehta, and M. Mehta, Recent progress and targets in drug resistance Overcoming multidrug-resistance in cancer: Statins offer a logical candidate Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies, Intern Med Med Hypotheses Pharmacol Rev, vol.428, issue.58, pp.237-280, 2003.

Z. Jin, Addition in drug combination Chemoinformatics: What is it and how does it impact. Drug discovery?, Zhongguo Yao Li Xue Bao Annu Rep Med Chem, vol.110, issue.33, pp.70-76, 1980.

J. Gasteiger, . Chemoinformatics, O. Jónsdóttir, S. Jørgensen, S. Brunak et al., Prediction methods and databases within chemoinformatics: Emphasis on drugs and drug candidates Recent advances in chemoinformatics Application of data mining approaches to drug delivery, 14] Ott A M, Vriend G. Correcting ligands, metabolites, and pathways, pp.57-64, 2005.

K. Ghose, T. Herbertz, M. Salvino, and P. Mallamo, Knowledgebased chemoinformatic approaches to drug discovery, Drug Discov Today, vol.112416, issue.23, pp.1107-1121, 2006.
DOI : 10.1016/j.drudis.2006.10.012

F. C. Blake, M. Gottesman, V. Ling, C. Chang, W. Swaan et al., The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research Computational approaches to modeling drug transporters A pharmacophore modeling approach to design new taxol ® . mimics: Towards the synthesis of potential anticancer and MDR-reversing agent. Issue Ital-Swiss Med Chem MeetTrimethoxyphenyl)-1-oxo-2-propene: A novel pharmacophore displaying potent multidrug resistance reversal and selective cytotoxicity Simulation of different truncated p16INK4a forms and in Silico Study of interaction with Cdk4 Characterization of an inhibitory dynamic pharmacophore for the ERCC1-XPA interaction using a combined molecular dynamics and virtual screening approach First pharmacophore-based identification of androgen receptor down-regulating agents: Discovery of potent anti-prostate cancer agents, Curr Opin Biotechnol FEBS Lett Eur J Pharm Sci ARKIVOC Bioorg Med Chem Cancer Inform J Mol Graph Model Bioorg Med Chem, vol.11171820212224, issue.1510, pp.104-111, 2000.

Y. Li, O. Polgar, L. Esser, S. Bates, and D. Xia, Towards understanding the mechanism of action of the multidrug resistance-linked half-ABC transporter ABCG2: A molecular modeling study, Journal of Molecular Graphics and Modelling, vol.25, issue.6, pp.837-51, 2007.
DOI : 10.1016/j.jmgm.2006.08.005

S. Mukherjee, S. Nagar, S. Mullick, A. Mukherjee, A. Saha et al., Pharmacophore mapping of arylbenzothiophene derivatives for MCF cell inhibition using classical and 3D space modeling approaches Functional assay and structure-activity relationships of new third-generation Pglycoprotein inhibitors Genomic and proteomic biomarkers for cancer: A multitude of opportunities, J Mol Graph Model Bioorg Med Chem Biochim Biophys Acta, vol.2626, issue.1796, pp.884-92, 2008.

A. Clarke, R. Poele, and P. Workman, Gene expression microarray technologies in the development of new therapeutic agents, European Journal of Cancer, vol.40, issue.17, pp.2560-91, 2004.
DOI : 10.1016/j.ejca.2004.07.024

M. Shi, Y. Fan, G. Myers, O. Connor, M. Paull et al., Mining the NCI anticancer drug discovery databases: Genetic function approximation for the QSAR study of anticancer ellipticine analogues A gene expression database for the molecular pharmacology of cancer Quantitative structure-activity relationship of multidrug resistance reversal agents, J Chem Inf Model Nat Genet Mol Pharmacol Genome Biol, vol.383032, issue.7, pp.189-99, 1997.

A. Amundson, G. Myers, D. Scudiero, S. Kitada, C. Reed et al., An informatics approach identifying markers of chemosensitivity in human cancer cell lines1 Functional study of multidrug resistance with fluorescent dyes. Limits of the assay for low levels of resistance and application in clinical samples, Cancer Res Cancer Lett, vol.6035, issue.362, pp.6101-6111, 1996.

A. Clarke, R. Poele, R. Wooster, P. Workman, L. Miller et al., Gene expression microarray analysis in cancer biology, pharmacology, and drug development: Progress and potential Gene expression profiling of leukemic cells and primary thymocytes predicts a signature for apoptotic sensitivity to glucocorticoids Mislocalized activation of oncogenic RTKs switches downstream signaling outcomes Drug discovery from medicinal plants, Nonpeptidic small-molecule inhibitor of Bcl-2 and Bcl-XL, pp.1311-1347, 2001.

. Gossypol, enhances biological effect of genistein against BxPC-3 human pancreatic cancer cell line, Pancreas, vol.3140, issue.4, pp.317-341, 2005.

C. Wu, F. Chen, J. Rushing, X. Wang, H. Kim et al., Antiproliferative Activities of Parthenolide and Golden Feverfew Extract Against Three Human Cancer Cell Lines, Journal of Medicinal Food, vol.9, issue.1, pp.55-61, 2006.
DOI : 10.1089/jmf.2006.9.55

M. Ammirante, D. Giacomo, D. Martino, A. Rosati, M. Festa et al., 1-Methoxy-Canthin-6-One Induces c-Jun NH2-Terminal Kinase-Dependent Apoptosis and Synergizes with Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Activity in Human Neoplastic Cells of Hematopoietic or Endodermal Origin, Cancer Research, vol.66, issue.8, pp.4385-93, 2006.
DOI : 10.1158/0008-5472.CAN-05-3895

C. Wang, J. Zhang, X. Shen, C. Wan, K. Tse et al., Reversal of P-glycoprotein-mediated multidrug resistance by Alisol B 23-acetate Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5- fluorouracil in HeLa cells Conferone from Ferula schtschurowskiana enhances vinblastine cytotoxicity in MDCK-MDR1 cells by competitively inhibiting Pglycoprotein transport, Biochem Pharmacol Biol Pharm Bull Planta Med J Immunother, vol.68434546, issue.292, pp.843-55, 2004.

F. Gaube, S. Wolfl, L. Pusch, C. Kroll, M. Hamburger et al., Gene expression profiling reveals effects of cimicifuga racemosa (L.) NUTT. (black cohosh) on the estrogen receptor positive human breast cancer cell line MCF-7 (in press) doi:10.1186/1471-2210-7-11 Increased therapeutic potential of an experimental anti-mitotic inhibitor SB715992 by genistein in PC-3 human prostate cancer cell line, BMC Pharmacol BMC Cancer Cancer Res, vol.74849, issue.661, pp.10553-10562, 2006.

Y. Li, O. Kucuk, M. Hussain, J. Abrams, L. Cher et al., Antitumor and antimetastatic activities of docetaxel are enhanced by Genistein through regulation of osteoprotegerin/Receptor activator of nuclear factor-KB(RANK)/RANK Ligand/MMP-9 signaling in prostate cancer Synergistic effects of protein tyrosine kinase inhibitor Genistein with camptothecins against three cell lines in vitro, Cancer Res Cancer Lett, vol.6651, issue.2332, pp.4816-4841, 2006.

Z. Mai, G. Blackburn, and J. Zhou, Soy phytochemicals synergistically enhance the preventive effect of tamoxifen on the growth of estrogen-dependent human breast carcinoma in mice, Carcinogenesis, vol.28, issue.6, pp.1217-1240, 2007.
DOI : 10.1093/carcin/bgm004

S. Carnesecchi, K. Langley, F. Exinger, F. Gosse, and R. F. , Geraniol, a Component of Plant Essential Oils, Sensitizes Human Colonic Cancer Cells to 5-Fluorouracil Treatment, Journal of Pharmacology and Experimental Therapeutics, vol.301, issue.2, pp.625-655, 2002.
DOI : 10.1124/jpet.301.2.625

N. Duarte, A. Varga, G. Cherepnev, R. Radics, J. Molnár et al., Apoptosis induction and modulation of P-glycoprotein mediated multidrug resistance by new macrocyclic lathyrane-type diterpenoids Pretreatment with neem (Azadirachta indica) leaf preparation in swiss mice diminishes leukopenia and enhances the antitumor activity of cyclophosphamide Notoginseng enhances anti-cancer effect of 5-fluorouracil on human colorectal cancer cells Induction of neutral endopeptidase activity in PC-3 cells by an aqueous extract of Epilobium angustifolium L. and oenothein B, Oleic acid, the main monounsaturated fatty acid of olive oil, suppresses HER-2/neu (erb B-2) expression and synergistically enhances the growth inhibitory effects of trastuzumab (Herceptine) in breast cancer cells with HER-2/neu oncogene amplification, pp.546-54, 2005.

C. Wu, F. Chen, J. Rushing, X. Wang, H. Kim et al., Perillyl alcohol and perillic acid induced cell cycle and apoptosis in non small cell lung cancer cells Synergistic cytotoxicity between tamoxifen and the plant toxin persin in human breast cancer cells is dependent on Bim expression and mediated by modulation of ceramide metabolism Proanthocyanidin from grape seeds enhances anti-tumor effect of doxorubicin both in vitro and in vivo Synergistic down-regulation of signal transduction and Cytotoxicity by Tiazofurin and quercetin in human ovarian carcinoma cells Effects of flavonoids on cisplatin-induced apoptosis of HL-60 and L1210 leukemia cells Reversal of multidrug resistance in cancer cells by rhizoma alismatis extract Evidence of a novel docetaxel sensitizer, garlic-derived Sallylmercaptocysteine , as a treatment option for hormone refractory prostate cancer, Solamargine induces apoptosis and sensitizes breast cancer cells to cisplatin, pp.55-61, 1999.

K. Kosugi, J. Sakai, S. Zhang, Y. Watanabe, H. Sasaki et al., Neutral taxoids from Taxus cuspidata as modulators of multidrug-resistant tumor cells Modes of action of alpha-hederin and thymoquinone, active constituents of Nigella sativa, against HEp-2 cancer cells, Phytochemistry Anticancer Res, vol.5470, issue.256B, pp.839-884, 2000.

S. Kim, Y. Kim, Y. Kim, L. J. Westfall, S. Nilsson et al., Role of triptolide as an adjunct chemotherapy for ovarian cancer Wogonin, a plant flavone, potentiates etoposide-induced apoptosis in cancer cells Novel dihydro-beta-agarofuran sesquiterpenes as potent modulators of human P-glycoprotein dependent multidrug resistance Multidrug resistance reversal agent, NSC77037, identified with a cell-based screening assay Modulation of multidrug resistance p-glycoprotein activity by flavonoids and honokiol in human doxorubicin-resistant sarcoma cells (MES-SA/DX-5): implications for natural sedatives as chemosensitizing agents in cancer therapy, cancer cells, pp.332-336, 1998.

M. Kawami, R. Yumoto, J. Nagai, V. Junyaprasert, N. Soonthornchareonnon et al., Effect of Thai plant extracts on P-glycoprotein function and viability in paclitaxelresistant HepG2 cells, Drug Metab Pharmacokinet, vol.2577, issue.2, pp.155-62, 2010.

C. Bailly, B. Da-rocha, M. Lopes, and G. Schwartsmann, Ready for a comeback of natural products in oncology Natural products in anticancer therapy, Biochem Pharmacol Curr Opin Pharmacol, vol.777980, issue.1, pp.1447-57, 2001.

X. Ma, W. Z. Nishibe, S. Sardari, S. Kodama, A. Horita et al., Anticancer drug discovery in the future: An evolutionary perspective Constituents of bark of Fraxinus Americana, Drug Discov Today Nat Med, vol.14248182, issue.515, pp.1136-142, 1997.

N. Stefanie, L. Donatella, E. W. Martino, D. Letizia, B. Enrico et al., Natural compounds for cancer treatment and prevention, Pharmacol Res, vol.83, issue.59, pp.365-78, 2009.

I. Abraham, P. Aristoff, and H. Skulnick, Protein kinase inhibitors and related compounds combined with taxol, p.7054, 1993.

J. Boik, P. Bobek, L. Ozdín, and S. Galbav, Natural compounds in cancer therapy: Promising nontoxic antitumor agents from plants & other natural sources Dose -and time-dependent hypocholesterolemic effect of oyster mushroom (Pleurotus ostreatus) in rats Cancer therapy, Am J Clin Nutr Nutrition, vol.7485, issue.143, pp.282-86, 1998.

J. Moodley and I. Coulter, Combination products, p.20080020018, 2008.

K. Chu, W. Xie, and C. Ho, Pharmaceutical composition and method for cancer treatment based on combinational use of conventional anticancer agents and geranium oil or compounds thereof, p.20080113042, 2008.

J. Hall and S. Beljanski, Flavopereirine and alstonine combinations in the treatment and prevention of prostate cancer, p.20090215853, 2009.

W. Xie, K. Li, E. Liu, and K. Chu, Cucurbitacin B and uses thereof, p.20090247495, 2009.

L. Ricciardiello, R. C. Boland, M. Roman, and V. Fogliano, Chemopreventive, anticancer and anti-inflammatory effects of pinoresinol-rich olives, p.20090048187, 2009.

A. E. Buck, A. Eyzaguirre, S. Bhagwat, S. Barr, and S. Russo, Combination anti-cancer therapy, p.20090274698, 2009.

A. Pichette and J. Legault, Potentiator of antitumoral agents in the treatment of cancer, p.20090286865, 2009.

J. Andrew, M. Lawrence, R. John, B. Gerald, S. Christine et al., Fixed ratio drug combination treatments for solid tumors, p.20090023680, 2009.

R. G. Lanzara, Method for determining drug-molecular combinations that modulate and enhance the therapeutic safety and efficacy of biological or pharmaceutical drugs, p.20090012717, 2009.

A. Potti, J. R. Nevins, and J. M. Lancaster, Predicting responsiveness to cancer therapeutics, p.20090105167, 2009.

S. Johnstone, P. Harvie, P. Tardi, T. Harasym, and L. Mayer, Combination formulations of cytidine analogs and platinum agents, p.20090074848, 2009.

O. Rangel and J. Angel, Prostate disorder(s) phyto-nutraceutical synergistic composition, p.20080260771, 2008.

H. Xu, G. L. Brown, S. R. Schow, and J. G. Keck, Combination cancer therapy with a GST-activated anticancer compound and another anticancer therapy, p.20080159980, 2008.

A. Borisy, D. Grau, B. R. Stockwell, and C. Keith, Screening system for identifying drug-drug interactions and methods of use thereof, p.20080194421, 2008.

A. Louie, C. Swenson, L. Mayer, and A. Janoff, Fixed drug ratios for treatment of hematopoietic cancers and proliferative disorders, p.20080199515, 2008.

S. Adimoolam, J. J. Buggy, D. Magda, and R. Miller, Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy, p.20080153877, 2008.

I. Scott, Methods to identify biologically active agents and synergistic combinations, p.20080026400, 2008.

S. Kim, B. J. An, H. Y. Kim, J. S. Kim, J. U. Kim et al., Method of improving anticancer effect of pulsatillae radix and a composition prepared by the method, p.20080268072, 2008.

T. J. Ekstrom, P. M. Almqvist, and T. Asklund, Compounds for enhanced cancer therapy, p.20070264241, 2007.

S. N. Gardner, Computational model, method, and system for kinetically-tailoring multi-drug chemotherapy for individuals, p.7286970, 2007.

M. X. Sliwkowski and S. M. Kelsey, Combination therapy of her expressing tumors, p.20070020261, 2007.

K. Parang, S. Sardari, and N. H. Nam, Azole derivatives and methods for making the same, p.20060142361, 2006.

K. G. Schwartz, B. Manor, and P. A. Albino, Combination of bryostatin and paclitaxel for treating cancer, p.7045495, 2006.

A. Chan, Q. Gong, and F. Martin, Combination therapy for B cell disorders, p.20050095243, 2005.

S. B. Horwitz, H. M. Mcdaid, and L. A. Martello, Method for treating neoplasia using combination chemotherapy, p.6541509, 2003.

F. Lee, Synergistic methods and compositions for treating cancer, p.6537988, 2003.

F. Wang, L. Wang, J. Yang, D. Chen, and X. Jian, Preparation and drug composition of bis-benzyl-isoquinoline class alkaloids, p.6617335, 2003.

B. J. Maurer and C. P. Reynolds, Treatment of hyperproliferative disorders, p.6368831, 2002.

S. M. Weissman and M. Snyder, Method for high throughput screening for anitbodies and proteins inducing apoptosis, p.20080145364, 2008.

M. Hidalgo and A. Jimeno, Methods to correct gene set expression profiles to drug sensitivity, p.20090221522, 2009.

L. Comanor and J. M. Minor, Method and apparatus for predicting therapeutic outcomes, p.5860917, 1999.

S. Tagashira and A. Fukushima, Combination drug for treating autoimmune disease, p.20080255121, 2008.

P. Tardi, C. Shew, A. Janoff, L. Mayer, M. Bally et al., Compositions for delivery of drug combinations, p.20060165771, 2006.

H. Hidaka, M. Matsuda, and F. Katoh, Medicinal composition and method for treating malignant tumor and utilization thereof, p.20060128762, 2006.

K. Sridhar, J. Gibbons, and J. James, Antineoplastic combinations comprising, p.6617333, 2003.

S. M. Weissnan and M. Snyder, Substrate potential generation circuit that can suppress variation of output voltage with respect to change in external power supply voltage and environment temperature, p.2006005434, 2006.

. Zhang, Load balance, double bucket cable stay crane with load sensing means, p.4039086, 2004.

R. Abraham, S. Schiaffino, K. Hajman, and E. Minatti, Combination therapy, p.20100004193, 2010.

B. N. Bryant, A. I. Damokosh, and G. Mulligan, Process for producing silicon carbide, p.6022515, 2006.

J. M. Minor, Plant fender or guard for cultivators, p.4026366, 2004.

J. Rubinfeld, Device for conveying metal sheets for affixation to a windup drum for winding thereon, p.4022367, 2004.

R. Stoughton and S. Stepaniants, Methods for drug interaction prediction using biological response profiles, p.6370478, 2002.

L. Comanor and J. M. Mimor, Method and apparatus for predicting therapeutic outcomes, p.633, 1998.

S. M. Moran and P. J. Langecker, Combination therapy for the treatment of estrogen-sensitive disease, p.20050130945, 2005.

S. Sardari, A. Shokrgozar, and G. Ghavami, Cheminformatics based selection and cytotoxic effects of herbal extracts, Toxicology in Vitro, vol.23, issue.7, pp.1412-1433, 2009.
DOI : 10.1016/j.tiv.2009.07.011

URL : https://hal.archives-ouvertes.fr/pasteur-00753306

G. Gh and S. Sardari, A novel algorithm for bioactive database compound library using bioinformatics methodology and cheminformatics tools. The first international congress on health genomics and biotechnology, pp.24-26, 2007.

D. M. Sullivan, J. G. Turner, T. C. Rowe, and D. A. Ostrov, Nuclear export inhibitors of topoisomerase II alpha, p.2010067922, 2010.

S. K. Michael, Methods for evaluating drug-resistance gene expression in the cancer patient, p.201011739673, 2010.

T. Uwaqawa, Antitumor agent containing 6'-amidino-2'-naphthyl 4- guanidinobenzoate or salt thereof, p.20100015249, 2010.

Z. Duan and F. J. Hornicek, compounds for reducing drug resistance and uses thereof, p.2010083385, 2010.

Y. G. Assaraf, E. E. Bram, Y. Bney-moshe, and A. M. Skladanowski, Imidazoacridinone derivative compounds and methods for their use, p.20100137351, 2010.

F. E. Romesberg and D. A. Bachovchin, Genomic mutation inhibitors that inhibit y family dna polymerases, p.20100130439, 2010.

Y. Hitoshi, S. Holland, and D. G. Payan, Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer, p.20100196511, 2010.

P. Kane and E. Kane, Combination therapy for modulation of activity and development of cells and tissues, p.20100022444, 2010.

G. Hedlund and G. Forsberg, Wallén-öhman, M. Treatment of hyperproliferative disease with superantigens in combination with another anticancer agent, p.20107763253, 2010.

W. Mcculloch and M. Keegan, Gemcitabine combination therapy, p.20100137239, 2010.

Y. K. Shin, H. S. Jung, and Y. Oh, Composition for treatment of cervix cancer, p.20100062051, 2010.

W. J. Van-de, Combination treatment of cd38-expressing tumors, p.20100092489, 2010.

K. Shailubhai and G. S. Jacob, Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders, p.20090048175, 2009.

E. Messersmith, Lieberburg, I. Methods and compositions for treating liquid tumors, p.20090312353, 2009.